Trial Profile
A Study to Evaluate the Efficacy and Tolerability of Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir With or Without Ribavirin in Patients With HIV-HCV Genotype 1 Coinfection
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 28 Dec 2016
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Expanded access; Therapeutic Use
- 28 Dec 2016 Status changed from recruiting to completed, according to results published in the Clinical Infectious Diseases.
- 22 Dec 2016 Results assessing safety and efficacy (n=213) published in the Clinical Infectious Diseases.
- 12 May 2016 New trial record